Upfront Fees, Milestones and Royalties from Out-Licensing Agreements
First written in FY2021. 2 of 3 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2021: 1 of 11 companies on the "Worse" side.
6 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「The drug discovery revenue model is to earn upfront payments from out-licensing drug candidates developed by the Company to pharmaceutical companies in Japan and overseas, milestone payments made according to development progress, and royalty revenue representing a certain percentage of sales after product launch, among other sources.」
Reconfirms that the revenue model consists of upfront payments at out-licensing, milestones tied to development progress and royalties after product launch. - FY2023RestatedAnnual report
「The drug discovery revenue model is to earn upfront payments from out-licensing drug candidates developed by the Company to pharmaceutical companies in Japan and overseas, milestone payments made according to development progress, and royalty revenue representing a certain percentage of sales after product launch, among other sources.」
Reconfirms that the drug discovery business's revenue model consists of upfront payments at out-licensing, milestones tied to development progress and royalties after product launch. - FY2021First statedAnnual report
「The drug discovery revenue model is to earn upfront payments from out-licensing drug candidates developed by the Company to pharmaceutical companies in Japan and overseas, milestone payments made according to development progress, and royalty revenue representing a certain percentage of sales after product launch, among other sources.」
Organizes drug discovery business revenue sources into stage-based revenue from out-licensing, development progress and the post-launch period.